# Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation

> **NCT02325362** · PHASE2,PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 16 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Miglustat ; placebo
- **DRUG:** Placebo ; Miglustat

## Key facts

- **NCT ID:** NCT02325362
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-17
- **Primary completion:** 2017-04-03
- **Final completion:** 2017-04-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02325362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02325362, "Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT02325362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*